Research Funding

  • July 15, 2009 - June 30, 2014 - The Response of Cancer and Stem/Progenitor Cells to Telomere Disruption , Principal Investigator . Sponsor: NIH, Sponsor Award ID: K08CA134552

Education

Swarthmore College, Swarthmore, PA, BA, 1995, Biology
Duke University, Durham, NC, PhD, 2002, Microbiology
Duke University, Durham, NC, MD, 2003, Medicine
University of California, San Francisco, CA, Resident/Fellow, 2003-2006, Anatomic Pathology
University of California, San Francisco, CA, Postdoctoral Fellow, 2005-2008, Biochemistry

Honors & Awards

  • 1995
    Phi Beta Kappa honor society
  • 1995
    Sigma Xi honor society
  • 1996-2003
    Medical Scientist Training Program Fellowship
  • 2005
    Ruth L. Kirschstein Postdoctoral Fellowship (declined)
  • 2005-2008
    American Cancer Society Postdoctoral Fellowship
  • 2010-present
    Mentored Clinical Scientist Development Award (K08)

Selected Publications

  1. Claire de la Calle, Nancy Greenland, Janet Cowan, Vittorio Fasulo, Martina Maggi, Emily Chan, Bradley Stohr, Jeffry Simko, Katsuto Shinohara, Matthew Cooperberg, Peter Carroll, Hao Nguyen. PD11-12 ASSOCIATIONS OF SERUM-BASED AND URINE-BASED MOLECULAR DIAGNOSTICS WITH HISTOLOGIC SUBTYPING ON PROSTATE BIOPSY. Investigative Urology. 2022 May 1; 207(Supplement 5):e194.  View on PubMed
  2. Sangoi AR, Chan E, Abdulfatah E, Stohr BA, Nguyen J, Trpkov K, Siadat F, Hirsch M, Falzarano S, Udager AM, Kunju LP. p53 null phenotype is a "positive result" in urothelial carcinoma in situ. Mod Pathol. 2022 09; 35(9):1287-1292.  View on PubMed
  3. Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J, Friedlander T, Fong L, Small EJ, Sweet-Cordero A, Koshkin VS. APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer. Front Oncol. 2022; 12:816706.  View on PubMed
  4. Peng Y, Greenland NY, Lang UE, Stohr BA. LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma. Pathol Res Pract. 2022 Apr; 232:153831.  View on PubMed
  5. Chan E, Stohr BA, Butler RS, Cox RM, Myles JL, Nguyen JK, Przybycin CG, Reynolds JP, Williamson SR, McKenney JK. Papillary Renal Cell Carcinoma With Microcystic Architecture Is Strongly Associated With Extrarenal Invasion and Metastatic Disease. Am J Surg Pathol. 2022 03 01; 46(3):392-403.  View on PubMed
  6. Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. Eur Urol Oncol. 2022 Dec; 5(6):714-718.  View on PubMed
  7. Tanya Jindal, Li Zhang, Jonathan Chou, David Shui, Sima P. Porten, Anthony C. Wong, Emily Chan, Bradley A. Stohr, Ivan de Kouchkovsky, Hala Borno, Rohit Bose, Daniel H Kwon, Arpita Desai, Franklin W. Huang, Rahul Raj Aggarwal, Eric Jay Small, Lawrence Fong, Terence W. Friedlander, Vadim S Koshkin. Biomarkers predictive of response to enfortumab vedotin (EV) treatment in advanced urothelial cancer (aUC). Journal of Clinical Oncology. 2022 Feb 20; 40(6_suppl):531-531.  View on PubMed
  8. Song H, Weinstein HNW, Allegakoen P, Wadsworth MH, Xie J, Yang H, Castro EA, Lu KL, Stohr BA, Feng FY, Carroll PR, Wang B, Cooperberg MR, Shalek AK, Huang FW. Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. Nat Commun. 2022 01 10; 13(1):141.  View on PubMed
  9. Greenland NY, Cooperberg MR, Wong AC, Chan E, Carroll PR, Simko JP, Stohr BA. Molecular risk classifier score and biochemical recurrence risk are associated with cribriform pattern type in Gleason 3+4=7 prostate cancer. Investig Clin Urol. 2022 01; 63(1):27-33.  View on PubMed
  10. Chen CV, Croom NA, Simko JP, Stohr BA, Chan E. Differential immunohistochemical and molecular profiling of conventional and aggressive components of chromophobe renal cell carcinoma: pitfalls for diagnosis. Hum Pathol. 2022 01; 119:85-93.  View on PubMed
  11. Heiko Yang, Hanbing Song, Paul Allegakoen, Jamie Xie, Kevin Lu, Bradley Stohr, Maxwell Meng, Sima Porten, Franklin Huang. MP66-08 SINGLE-CELL TRANSCRIPTIONAL PROFILES OF HISTOLOGIC VARIANTS IN BLADDER CANCER. Investigative Urology. 2021 Sep 1; 206(Supplement 3).  View on PubMed
  12. Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J. Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. Clin Cancer Res. 2021 09 15; 27(18):5123-5130.  View on PubMed
  13. Tang S, Meng MV, Slater JB, Gordon JW, Vigneron DB, Stohr BA, Larson PEZ, Wang ZJ. Metabolic imaging with hyperpolarized 13 C pyruvate magnetic resonance imaging in patients with renal tumors-Initial experience. Cancer. 2021 08 01; 127(15):2693-2704.  View on PubMed
  14. Carissa Chu, Martin Sjöström, Emily A Egusa, Ewan Gibb, Michelle L Badura, Vadim S Koshkin, Bradley A. Stohr, Maxwell Meng, Raj Pruthi, Terence W. Friedlander, Yair Lotan, Peter C. Black, Sima P. Porten, Felix Y Feng, Jonathan Chou. Heterogeneity in Nectin-4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):463-463.  View on PubMed
  15. Greenland NY, Cowan JE, Chan E, Carroll PR, Stohr BA, Simko JP. Prostate biopsy histopathologic features correlate with a commercial gene expression assay's reclassification of patient NCCN risk category. Prostate. 2020 12; 80(16):1421-1428.  View on PubMed
  16. Anderson JA, Matoso A, Murati Amador BI, Cheng L, Stohr BA, Chan E, Osunkoya AO. Invasive poorly differentiated adenocarcinoma of the bladder following augmentation cystoplasty: a multi-institutional clinicopathological study. Pathology. 2021 Feb; 53(2):214-219.  View on PubMed
  17. D. Natesan, L. Zhang, H. Martell, P. Devine, B. Stohr, J. Grenert, J. Van Ziffle, N. Joseph, B.C. Bastian, S. Umetsu, C. Onodera, E. Chan, A. Desai, S. Porten, J. Chou, T. Friedlander, L. Fong, E.J. Small, A. Sweet-Cordero, V.S. Koshkin. APOBEC signatures and high tumour mutational burden as predictors of clinical outcomes and response to therapy in patients with urothelial carcinoma. Annals of Oncology. 2020 Sep 1; 31:s593.  View on PubMed
  18. Sangoi AR, Chan E, Stohr BA, Kunju LP. Invasive plasmacytoid urothelial carcinoma: A comparative study of E-cadherin and P120 catenin. Hum Pathol. 2020 08; 102:54-59.  View on PubMed
  19. Divya Natesan, Henry Martell, Patrick Devine, Bradley A. Stohr, James P. Grenert, Jessica Van Ziffle, Nancy M. Joseph, Boris C. Bastian, Sarah E Umetsu, Courtney Onodera, Emily Chan, Arpita Desai, Anthony C. Wong, Sima P. Porten, Jonathan Chou, Terence W. Friedlander, Eric Jay Small, Lawrence Fong, Eric Alejandro Sweet-Cordero, Vadim S Koshkin. Correlation of tumor mutational burden (TMB) with molecular profiling and clinical characteristics in patients with bladder cancer. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):e17025-e17025.  View on PubMed
  20. Lei L, Stohr BA, Berry S, Lockwood CM, Davis JL, Rudzinski ER, Kunder CA. Recurrent EGFR alterations in NTRK3 fusion negative congenital mesoblastic nephroma. Pract Lab Med. 2020 Aug; 21:e00164.  View on PubMed

Go to UCSF Profiles, powered by CTSI